Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, immunology, and infectious diseases. The company specializes in using its proprietary technology platforms to develop novel therapies for conditions such as neurological disorders, grief, fibromyalgia, and COVID-19.
Company News
Tonix Pharmaceuticals received FDA clearance to proceed with a Phase 2 HORIZON study of TNX-102 SL, a potential new treatment for major depressive disorder, targeting 360 patients across 30 U.S. sites with planned enrollment in mid-2026.
Tonix Pharmaceuticals launched TONMYA, the first FDA-approved fibromyalgia treatment in over 15 years, offering a novel, non-opioid, once-daily bedtime analgesic for the estimated 10 million adults suffering from the chronic pain disorder.
Tonix Pharmaceuticals is collaborating with Massachusetts General Hospital to conduct a Phase 2 clinical trial of TNX-1500, a monoclonal antibody designed to prevent kidney transplant rejection with potentially reduced immunosuppressive drug side effects.
Tonix Pharmaceuticals presented Phase 3 RESILIENT study data on Tonmya, demonstrating significant pain reduction in fibromyalgia patients with minimal side effects. The drug was FDA-approved in August 2025 and shows promise as a well-tolerated, non-opioid treatment.
Tonix Pharmaceuticals presented preclinical data for TNX-801, a live virus vaccine candidate designed to protect against mpox and smallpox, demonstrating favorable safety, immunogenicity, and long-term protection across multiple animal models.
